补肺活血胶囊治疗COPD大鼠的血清代谢组学与网络药理学机制研究
该研究以香烟熏吸联合LPS气道滴入90天建立COPD大鼠模型,灌胃给药30天后评估肺功能、病理及炎症氧化指标,并行血清代谢组学与网络药理学分析。结果发现补肺活血胶囊可改善肺功能与病理改变,调节46个COPD生物标志物中的23个,并通过花生四烯酸代谢通路发挥抗炎抗氧化保护作用。
要点
- 补肺活血胶囊可改善COPD大鼠肺功能、免疫、肺组织病理及胶原沉积。
- 其机制可能与抑制COX2和5-LOX、调控花生四烯酸代谢通路有关。
- 代谢组学发现46个COPD生物标志物,BHC显著回调其中23个。
核心结论
- 补肺活血胶囊通过花生四烯酸代谢通路发挥抗炎和抗氧化作用,对COPD模型大鼠具有保护效应。
研究设计与样本
- 采用香烟熏吸联合脂多糖气道滴入连续90天建立COPD大鼠模型,灌胃给药30天后进行评估。
- 整合血清代谢组学(UHPLC-Q-TOF/MS)与网络药理学分析,并用WB和ELISA验证关键通路。
主要发现
- BHC可改善COPD大鼠肺功能、免疫、肺组织病理改变及胶原沉积。
- BHC显著降低体内炎症反应,调节氧化应激水平,降低层粘连蛋白含量,调节蛋白酶-抗蛋白酶平衡。
- 代谢组学发现46个COPD生物标志物,BHC显著改善其中23个差异代谢物水平,包括花生四烯酸、白三烯B4和前列腺素E2。
- 网络药理学提示毛蕊异黄酮、氧化芍药苷、(S)-巴伐 chin 和新巴伐异黄酮等成分可能通过花生四烯酸通路发挥治疗作用。
- WB和ELISA结果显示BHC可抑制肺组织中COX2和5-LOX表达,并抑制血清中花生四烯酸及其代谢物的生成。
临床怎么用
- 该研究为补肺活血胶囊治疗COPD提供了实验依据,支持其抗炎抗氧化及调控花生四烯酸代谢通路的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Bufei Huoxue capsule (BHC) as a classic Chinese patent medicine formula, has the efficacy of tonifying the lungs and activating the blood. It has been extensively used in China for the treatment of chronic obstructive pulmonary disease (COPD) clinically. However, its mechanism is still unclear, which hampers the applications of BHC in treating COPD. AIM OF THE STUDY: The purpose of the present study was to demonstrate the protective efficacy and mechanism of BHC on COPD model rats by integrating serum metabolomics analysis and network pharmacology study. MATERIALS AND METHODS: A COPD rat model was established by cigarette fumigation combined with lipopolysaccharide (LPS) airway drip for 90 consecutive days. After oral administration for 30 days, the rats were placed in the body tracing box of the EMKA Small Animal Noninvasive Lung Function Test System to determine lung function related indexes. Histopathological alteration was observed by H&E staining and Masson staining. The serum levels of inflammatory cytokine, matrix metalloprotein 9, and laminin were determined by ELISA kits. Oxidative stress levels were tested by biochemical methods. UHPLC-Q-TOF/MS analysis of serum metabolomics and network pharmacology were performed to reveal the bioactive metabolites, key components and pathways for BHC treating COPD. WB and ELISA kits were used to verify the effects of BHC on key pathway. RESULTS: BHC could improve lung function, immunity, lung histopathological changes and collagen deposition in COPD model rats. It also could significantly reduce inflammatory response in vivo, regulate oxidative stress level, reduce laminin content, and regulate protease-antiprotease balance. Metabolomics analysis found 46 biomarkers of COPD, of which BHC significantly improved the levels of 23 differential metabolites including arachidonic acid, leukotriene B4 and prostaglandin E2. Combined with the results of network pharmacology, the components of BHC, such as calycosin, oxypaeoniflora, (S)-bavachin and neobavaisoflavone could play therapeutic roles through the arachidonic acid pathway. In addition, the results of WB and ELISA indicated that BHC could suppress the expressions of COX2 and 5-LOX in lung tissues and inhibit the generation of AA and its metabolites in serum samples. Regulation of arachidonic acid metabolic pathway may be the crucial mechanism for BHC treating COPD. CONCLUSIONS: In summary, the studies indicated that BHC exhibited the protective effect on COPD model rats by anti-inflammatory and anti-oxidative properties through arachidonic acid metabolism pathway. This study provided beneficial support for the applications of BHC in treating COPD.
引用
- Ren H, Wu W, Chen J, et al. Integrated serum metabolomics and network pharmacology analysis on the bioactive metabolites and mechanism exploration of Bufei huoxue capsule on chronic obstructive pulmonary disease rats. J Ethnopharmacol. 2024. PMID: 38286154. doi:10.1016/j.jep.2024.117816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。